To test the safety and efficacy of Omecamtiv Mecarbil in patients with chronic heart failure with reduced ejection fraction.
Principal Investigator: David Rawitscher, MD
Locations: Legacy Heart Center Plano, Congestive Heart Failure Center Plano, Baylor Scott & White The Heart Hospital – Plano, The Heart Group Plano and The Heart Group McKinney
IRB Number: 017-020
Trial Status: Enrolling
Exclusions: Adults only
Change in Care: Participating will change your care
Alexandria Biberstein, RN469.814.4732Alexandria.Biberstein@BSWHealth.org
A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of Omecamtiv Mecarbil on mortality and morbidity in subjects with chronic heart failure with reduced ejection fraction.
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.